Glenmark loses jury verdict in DNJ over Tarka
The WSJ reports that Glenmark lost a jury verdict in the District of New Jersey related to Glenmark's selling (at risk) a generic version of hypertension drug Tarka.
Bloomberg had reported on January 14:
The patent is for an angiotensin-converting enzyme inhibitor with a calcium channel blocker. Tarka combines the ACE inhibitor trandolapril with verapamil hydrochloride. Glenmark said the patent differed little from ones covering other ACE inhibitors, including the compounds quinapril and ramipril.
Abbott argued that Tarka was different than the earlier combinations, and pointed to the success of the drug as evidence that it was unique. The Abbott Park, Illinois-based company doesn’t break out sales of the drug.
Abbott has said a competing generic version of Tarka would cost the company $150 million to $270 million in business during the remaining life of the patent, according to court records. Abbott reported $30.8 billion in sales in 2009.
Bloomberg had reported on January 14:
The patent is for an angiotensin-converting enzyme inhibitor with a calcium channel blocker. Tarka combines the ACE inhibitor trandolapril with verapamil hydrochloride. Glenmark said the patent differed little from ones covering other ACE inhibitors, including the compounds quinapril and ramipril.
Abbott argued that Tarka was different than the earlier combinations, and pointed to the success of the drug as evidence that it was unique. The Abbott Park, Illinois-based company doesn’t break out sales of the drug.
Abbott has said a competing generic version of Tarka would cost the company $150 million to $270 million in business during the remaining life of the patent, according to court records. Abbott reported $30.8 billion in sales in 2009.
posted by Lawrence B. Ebert at 8:31 AM
0 Comments:
Post a Comment
<< Home